Barinthus Bio’s VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

June 6, 2024

https://www.globenewswire.com/news-release/2024/06/06/2894848/0/en/Barinthus-Bio-s-VTP-300-Trials-Demonstrate-Ability-to-Achieve-Undetectable-HBsAg-levels-and-Statistical-Significance-in-Lowering-HBsAg-Levels-in-People-with-Chronic-Hepatitis-B.html

OXFORD, United Kingdom, June 06, 2024 (GLOBE NEWSWIRE) — Barinthus Biotherapeutics plc (NASDAQ:BRNS), a biopharmaceutical company developing novel T cell immunotherapeutic candidates, today announced the presentation of updated data from two clinical trials in people with chronic hepatitis B (CHB) at the European Association for the Study of the Liver (EASL) Congress 2024. The presentations include updated interim data from the Phase 2b clinical trial (HBV003), as well as new interim EOT data from the Phase 2a clinical trial (IM-PROVE II, AB-729-202) in partnership with Arbutus Biopharma (NASDAQ:ABUS), both in people with CHB receiving ongoing SoC NUC therapy.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.